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Abstract
Background: Developing new medicines relies on the successful conduct of clinical trials. As trial protocols
become more arduous, it becomes harder to recruit and retain patient volunteers, although recent efforts such as
OMERACT and I-SPY2 show that partnering with patients can be beneficial. We sought to describe drivers and
barriers to trial participation, as well as condition-specific trial preferences.
Methods: An online survey was fielded via the patient-powered research network PatientsLikeMe to 1,621
members living with nine selected chronic health conditions. Questions included demographics, trial experience,
reasons for non-participation, questions relating to aspects of trial design, and an adaptation of the Net Promoter
Score (NPS) for trial satisfaction.
Results: Mean age of respondents was 55 years; most patients were white (93%), female (67%), and living in the
United States (72%). Primary conditions were MS (21%), Parkinson’s (20%), fibromyalgia (15%), ALS (10%), type 2
diabetes (10%), rheumatoid arthritis (RA, 8%), epilepsy (8%), major depressive disorder (MDD, 5%) and systemic
lupus erythematosus (SLE, 3%). Most patients had not discussed a trial with their physician and only 21% had ever
enrolled, with rates highest in ALS (36%), Parkinson’s disease (36%) and MS (20%) and lowest among SLE (9%), MDD
(11%) and Fibromyalgia (11%). Common reasons for non-participation were eligibility criteria, inconvenience of
travel and concerns about side effects. NPS suggested that many patients were unsatisfied; patients with lupus,
epilepsy, RA, and fibromyalgia reported negative scores, i.e. they would dissuade other patients like them from
taking part in trials. The most important considerations in trial participation were the opportunity to improve one’s
own health and that of others, the reputation of the institution, and having medical bills covered in case of injury.
Least important were remuneration and possibility of receiving a placebo. ALS patients were more willing to
tolerate undesirable aspects of trials.
Conclusions: Most patients are willing to enroll yet very few are invited. When they do, trial participation is often
burdensome, but patients are willing to help improve their design. Researchers should let patients help design
better trials to overcome recruitment and retention issues and hasten the development of new medicines.
Keywords: Clinical trials, Engagement, Recruitment, Retention, Patient-centeredness, Trial design
Background
The development of new and innovative medicines is be-
ing hampered by the rising cost of clinical trials [1], with
one estimate for the cost of bringing a drug to market as
$2.6 billion, a 145% increase from 2003 [2]. Despite energy
and resources devoted to study planning, protocol devel-
opment, and physician reimbursement, many studies fail
to recruit enough patients to be adequately powered, and
a subset even fail to recruit any patients [3–5]. Even once
recruited, patients may still choose to prematurely drop
out of a trial, compromising the study’s validity [6]. Tools
and strategies that overcome challenges to recruitment
and retention have the potential to reduce costs and so ac-
celerate research, but this first requires a thorough under-
standing of the potential barriers. These include (1)
organizational factors, (2) healthcare professional factors,
and (3) patient factors [7, 8].
Many patients harbor misconceptions about trials; in a
survey of nearly 6,000 patients, 37% thought their med-
ical care would be better if they did not enroll in a trial,* Correspondence: pdasmahapatra@patientslikeme.com
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and 22% believed enrolling in a clinical trial would lead
to them being “treated like a guinea pig” [9]. Such fears
are not completely unfounded given that that participat-
ing in a trial is increasingly burdensome, with the me-
dian number of study procedures that patients must
endure rising from 20 per protocol in 2000–2003 to 30
in 2008–2011 [10]. Listening effectively to patients at
early stages may uncover patient-facing obstacles, facili-
tating effective planning and minimizing burden.
Patient-centered approaches to study design and execu-
tion might even yield more successful studies [11] and
methods to support higher levels of patient engagement
have been successfully introduced by research groups
such as the OMERACT group [12] and the I-SPY2 trial
[13]. In both examples, patients helped resolve research
challenges by (1) addressing undesirable aspects of trials,
(2) surfacing new perspectives to researchers, (3) inter-
acting directly with researchers, and (4) co-producing
new resources that patients may find beneficial before,
during and after the trials [14].
Such examples are few and far between, however, and
the potential to prevent costly and avoidable protocol
amendments [15] has stimulated interest to systematic-
ally involve patients in trial designs on a wider scale.
However, deployment of patient-centered engagement
models are challenging to implement and sustain over a
period of time. Patient-powered research networks
(PPRNs) might offer one useful model to streamline
real-time patient input into clinical trial planning, having
the advantage of inherent scalability, reaching patients in
their homes, and having lower barriers than traditional
methods to ask multiple rounds of iterative questions
[16]. We sought to conduct a pilot study with one
PPRN, PatientsLikeMe (PLM), to understand motiva-
tions and barriers to trial participation, and to identify
opportunities to enhance the clinical trial experiences of
patients with chronic disease. As a pilot study, explora-
tory objectives were to (1) identify socio-demographic
factors associated with trial participation; and (2) explore
the differences in perceptions and attitudes about trials
by type of chronic conditions. The long-term objective
of this study was to build a systematic infrastructure to
engage patients in trial design so that academics and
pharmaceutical companies investigating new drugs could
quickly draw upon evidence to optimize the design of
each unique trial.
Methods
Setting and study design
Members of PatientsLikeMe share data about their con-
ditions, treatments, symptoms and comorbidities
through structured data collection in order to connect
with other patients like them, manage their condition,
and contribute to scientific research [17]. An online
survey was administered to members of the PLM web-
site between February and March 2014. The survey
items were developed with the intention of elucidating
patient perceptions and experience of clinical trials. De-
velopment and usability pre-testing were performed it-
eratively by the authors. The survey was then reviewed
for editorial and technical suggestions by the Quality As-
surance staff at PLM. Invitations were sent via private
electronic message to an unrestricted convenience sam-
ple of members. Completion of the entire survey took
about 15 min and was shorter for those who skipped or
branched out of sub-sections. Given that participation in
the survey was voluntary and members were not remu-
nerated for their participation, patients were unlikely to
provide spurious data, although no formal validation of
data accuracy was undertaken. Survey responses were
collected using a proprietary survey tool and stored in a
secure database.
Independent ethics review was not sought as members
(patients) of the PLM community are informed of their
involvement in research activities via the user agreement
and privacy policy before joining the site. Further, the
study falls under Office for Human Research Protections
(OHRP) Exempt Categories 45 CFR 46.101(B) i.e., re-
search involving the use of educational tests (cognitive,
diagnostic, aptitude, achievement), survey procedures,
interview procedures or observation of public behavior.
Measures
Demographic variables included age, sex, ethnicity,
race, country of residence, and primary medical con-
dition. The survey included three major sections: (1)
past experience with clinical trials; (2) attitudes and
interest towards clinical trials; and (3) perceived fac-
tors that might influence clinical trial participation.
Skip-logic and conditional branching were embedded
within the survey. Response options varied by the
type of questions and ranged from numerical, categor-
ical, ordinal (Likert scale) to open ended comments.
Multiple-choice questions with “select all that apply”
response choice were randomized to avoid primacy
and recency effects. An adaptation of Net Promoter
Score (NPS), a single item measure of consumer sat-
isfaction [18] was used to assess trial performance
across conditions. NPS has been used as an overarch-
ing measure of patient experience with healthcare de-
livery. Patients were asked “How likely would you be
to recommend taking part in this specific trial to an-
other eligible patient like you?” (0–6: detractors, 7–8:
passive and 9–10: promoters). A NPS score was cal-
culated as the percentage of respondents who were
promoters and subtracting the percentage that were
detractors. A copy of the survey as fielded to partici-
pants is supplied in Additional file 1: Appendix E-1.
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Participants
Participants were selected from the PLM database of pa-
tients with the nine most frequently reported “primary”
conditions (i.e. a member’s chief complaint). The inclusion
criteria were: (1) Registered members of the PLM website,
(2) aged 18 years or over, (3) website activity within the
past 90 days, (4) Reporting one of the following 9 primary
medical conditions - amyotrophic lateral sclerosis (ALS),
type 2 diabetes mellitus (T2DM), epilepsy, fibromyalgia,
multiple sclerosis (MS), major depressive disorder (MDD),
Parkinson’s disease (PD), rheumatoid arthritis (RA), or
systemic lupus erythematosus (SLE) on their PLM profile.
Data analyses
Analyses were only conducted in patients who completed
the entire survey. Duplicate entries were removed from
analyses. Descriptive statistics were computed for demo-
graphic variables and presented as mean (SD) for continu-
ous variable age and frequency (%) for categorical
variables sex, race, region, ethnicity and primary medical
condition. Difference in demographic distribution between
groups (e.g., completers vs. non-completers, trial experi-
ence vs. no prior trial experience) were tested using t-test
for age and χ2 test for categorical variables. Questions per-
taining to awareness, participation and interest in clinical
trials were reported as frequency (%) for categorical vari-
ables. The measure of association between socio-
demographic factors and trial participation was presented
as Odds ratio (OR). Data analyses were performed for all
survey completers as well as stratified by the primary con-
dition. Differences between primary conditions were
tested by using the MULTTEST procedure with bootstrap
adjusted p-values for pairwise comparisons, where appro-
priate. Data analyses were performed in SAS version 9.4
(SAS Institute Inc., Cary, NC). The level of significance




Six thousand eight hundred and nineteen (n = 6,819)
unique members were invited to participate in the survey
of which 6,815 met the eligibility criteria. Two thousand
four hundred and thirty-seven (n = 2,437) viewed the invi-
tation resulting in a view rate (n of views/n of eligible in-
vites) of 36%. Among those who viewed the invite (n =
2,437), 1,621 completed the survey, 636 opted out, and
180 provided partial data, yielding participation rate (n of
participation/n of views) and completion rate (n of com-
pleters/n of participation) of 74% and 90%, respectively
(Fig. 1). The completion rate was in line with Internet-
based surveys of similar length (approximately 70%) [19].
Among completers, the mean age of members at the
time of the survey was 55 years (SD: 11 years); 67% (n =
1,078) were female, 93% were white (n = 1,473). The pri-
mary conditions cited by completers were multiple scler-
osis (21%, n = 343), Parkinson’s disease (20%, n = 319),
fibromyalgia (15%, n = 241), amyotrophic lateral sclerosis
(10%, n = 160), type 2 diabetes mellitus (10%, n = 158),
rheumatoid arthritis (8%, n = 125), epilepsy (8%, n =
131), major depressive disorder (5%, n = 91) and sys-
temic lupus erythematosus (3%, n = 53) (Table 1). The
majority of members were from the United States (72%,
n = 1,168), United Kingdom (10%, n = 158), Canada (8%,
n = 134) and Australia (3%, n = 50).
Using available profile data from non-completers,
completers were around 3 years older than non-
completers (t-test = 7.7, p < 0.0001). The groups also dif-
fered significantly on primary condition (χ2 = 283.1, p <
0.0001). Of note, the percentage of completers relative
to non-completers were higher for MS (21% vs. 13%),
fibromyalgia (15% vs. 8%) and PD (20% vs 13%); and
lower for T2DM (10% vs. 21%) and MDD (5% vs. 9%)
(Table 1). The demographics of trial completers broken
down by condition are shown in Table 2.
Patient experience with trials
In our study population, 39% (n = 630/1621) of patients
reported having discussed medical research with their
Fig. 1 Flow of participation in the survey. Six-thousand eight-
hundred and nineteen patients (n = 6,819) were invited of which n
= 2,437 viewed the invite and n = 1,621 completed the survey, yield-
ing view rate (n of views/n of eligible invites), participation rate (n of
participation/n of views) and completion rate (n of completers/n of
participation) of 36%, 74 and 90%, respectively
DasMahapatra et al. BMC Health Services Research  (2017) 17:166 Page 3 of 10
physician and 31% (n = 496/1621) reported being invited
to participate in a clinical trial. One-fifth (21%) of pa-
tients had ever enrolled in a clinical trial (i.e. were “trial
experienced”) (n = 346/1,621, Table 2) with 65% of the
trial experienced subgroup (n = 222/346) completing one
or more trial(s). About a quarter, 24% (n = 82/346) were
enrolled in a trial at the time of the survey and 12% (n =
42/346) had withdrawn from a trial before its conclu-
sion. Among trial experienced patients, the mean age at
the time of the survey was higher (57 years vs. 54 years)
compared to those without prior trial experience. The
proportion of trial experienced patients was highest
among patients with ALS (36%, n = 57/160), Parkinson’s
disease (36%, n = 116/319) or MS (20%, n = 67/343); and
lowest among those with SLE (9%, n = 5/53), MDD
(11%, n = 10/91) or fibromyalgia (11%, n = 26/241)
(Table 1). Among those invited to a trial some did not
meet the eligibility criteria (19%, n = 93/496) and a few
declined to participate (11%, n = 57/496). The reasons
cited for declining participation in trials include, in de-
scending order: inconvenience of travel (42%, n = 24/57),
concerns about side effects (30%, n = 17/57), chance of
getting a placebo (23%, n = 13/57) and having no interest
in the particular trial (23%, n = 13/57) (Fig. 2). Socio-








N 6,815 1,621 5,194
Age (years) a 7.7 <0.0001
Mean ± SD 53 ± 13 55 ± 11 52 ± 13
Unknown, N (%) 231 (3%) 0 (0%) 231 (4%)
Sex, N (%)a 0.0 0.989
Female 4,390 (65%) 1,078 (67%) 3,312 (64%)
Male 2,210 (32%) 543 (33%) 1,667 (32%)
Unknown 215 (3%) 0 (0%) 215 (4%)
Primary Condition, N (%) 283.1 <0.0001
ALS 833 (12%) 160 (10%) 673 (13%)
T2DM 1,249 (18%) 158 (10%) 1091 (21%)
Epilepsy 556 (8%) 131 (8%) 425 (8%)
Fibromyalgia 665 (10%) 241 (15%) 424 (8%)
MS 1,000 (15%) 343 (21%) 657 (13%)
MDD 543 (8%) 91 (5%) 452 (9%)
PD 998 (15%) 319 (20%) 679 (13%)
RA 624 (9%) 125 (8%) 499 (10%)
SLE 346 (5%) 53 (3%) 293 (5%)
SD Standard deviation
a Only available data (excluding unknown) used for statistical comparison between completers and non-completers
Table 2 Demographic Characteristics by Primary Condition among Completers
N Age (Mean ± SD) Sex (Female) Race (White) Trial experience
ALS 160 58 ± 10 65 (41%) 152 (95%) 57 (36%)
T2DM 158 58 ± 9 79 (50%) 138 (87%) 20 (13%)
Epilepsy 131 47 ± 12 83 (63%) 115 (88%) 25 (19%)
Fibromyalgia 241 52 ± 10 220 (91%) 228 (95%) 26 (11%)
MS 343 51 ± 9 246 (72%) 300 (87%) 67 (20%)
MDD 91 44 ± 12 58 (64%) 83 (91%) 10 (11%)
PD 319 63 ± 8 171 (54%) 306 (96%) 116 (36%)
RA 125 54 ± 10 105 (84%) 107 (86%) 20 (16%)
SLE 53 49 ± 12 51 (96%) 44 (83%) 5 (9%)
All Completers 1,621 55 ± 11 1078 (67%) 1473 (91%) 346 (21%)
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demographic factors that were associated with trial
participation were: discussing medical research with
physician (OR 11.2, 95% CL 8.3–15.1), US residence (OR
1.6, 95% CL 1.2–2.1), and male sex (OR 1.4, 95% CL
1.1–1.7) (Fig. 3).
The majority of trial experienced participants (58%, n
= 200) reported being “extremely” to “very satisfied” with
their participation while a fifth (20%) were only “slightly”
or “not at all” satisfied. An overall trial satisfaction as
measured by NPS, revealed that 46% (n = 159/346) were
classified by the scoring system as “promoters” and 34%
(n = 119/346) were “detractors” yielding an average score
(% promoters - % detractors) of 12% (95% CI: 7% to
17%. Fig. 4). NPS was higher in patients with Parkinson’s
disease (NPS: 22%, 95% CI: 14% to 30%) and MS (NPS:
18%, 95% CI: 7% to 29%); and lower in RA (NPS: −10%,
95% CI: −29% to 9%) and Epilepsy (NPS: −16%, 95% CI:
−34% to 2%), where some participants would actively
dissuade other patients like them from taking part in
trials.
At the time of the survey, the mean age of participants
who withdrew before trial conclusion was 58 years. Trial
withdrawal was higher in females (16%, n = 33/211) rela-
tive to males (7%, n = 9/135). The proportion of trial
withdrawal was highest among patients with SLE (40%,
n = 2/5) and MS (21%, n = 14/57). NPS was also notably
lower in patients who withdrew from trials (NPS: −28%,
95% CI: −52% to −24%) relative to those who completed
or were in a trial at the time of the survey (NPS: 18%,
95% CI: 13% to 23%).
Overall attitudes toward trials
Participants expressed a high degree of interest in clin-
ical trials. Specifically, 88% (n = 1,434/1,621) agreed they
were “Interested in learning more about taking part in
trials” and 80% (n = 1,288/1,621) agreed to “I would like
to take part in a trial in the next 12 months”. Finally,
93% (n = 1,503/1,621) agreed that they would be “Inter-
ested in helping researchers to design better trials”,
Fig. 2 Reasons for declining trial participation amongst those that
declined. The most common reasons were travel inconvenience,
concerns over side effects and no interest in particular trial. Mistrust
of sponsors, insufficient compensation and advice from family/
friends were the least cited reasons. Note: Categories not mutually
inclusive; percentages sum to greater than 100%
Fig. 3 Factors associated with Participation in Trials. Socio-
demographic factors that were associated with trial participation
were: discussing medical research with physician (OR 11.2, 95% CL
8.3–15.1), US residence (OR 1.6, 95% CL 1.2–2.1), and male sex (OR
1.4, 95% CL 1.1–1.7)
Fig. 4 a, b. Trial satisfaction (a) and Net Promoter Score (b) by
primary condition (patient’s chief complaints). Patients with
Parkinson’s disease and MS were likely to endorse trials to other
patients; in RA and Epilepsy participants were more likely to
dissuade other patients like them from taking part in trials. Overall,
58% patients were “Very” to “Extremely” satisfied with the trials they
partook in. Error bars represent 95% Confidence Intervals (95% CI)
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suggesting an opportunity to engage with this population
again on a trial-by-trial basis to develop better protocols
and engagement methods.
When asked to rate factors they might consider be-
fore joining a clinical trial, participants cited the fol-
lowing factors as “very” to “somewhat” important (in
descending order of ratings): (1) opportunity to im-
prove health of others (98%, n = 1,593/1,621) and self
(98%, n = 1,586/1,621), (2) reputation of the institution
)97 %, n = 1,578/1,621), and (3) covering medical bills
in case of a trial related injury (96%, n = 1,551/1,621).
The least important considerations were: (1) remuner-
ation for participation (46%, n = 734/1,621), and (2)
receiving a placebo (64%, n = 1,046/1,621). Perceived
importance of these factors across conditions and sig-
nificant pairwise differences are shown in Table 3.
Condition-specific attitudes toward trials
The perceptions of ALS patients were significantly dif-
ferent from other patients on a number of factors, sug-
gesting that patients with this more serious and lethal
disease would be more accommodating around issues of
side effects, privacy and confidentiality, having their bills
covered, receiving results after the study, changing doc-
tors during the trial, and not receiving remuneration for
taking part. For nearly every other factor, all non-ALS
conditions were in agreement. However, there were
more between-group differences on the issue of being
paid to participate in a trial, with higher levels of interest
expressed by patients with epilepsy (63%), type II dia-
betes (60%), RA (58%), and SLE (58%) relative to pa-
tients with Parkinson’s (32%) or ALS (19%). Three of the
four groups expressing an interest in being paid were
also those with the lowest NPS score.
Discussion
In a survey of over 1,600 patients with chronic illnesses,
we found a high degree of willingness to take part in tri-
als but a low degree of trial experience and variable rate
of trial satisfaction among those that had ever taken
part. Online platforms might provide a means for identi-
fying and perhaps even resolving some of the challenges
to recruitment and retention before they happen by ask-
ing patients to partner with researchers to improve their
studies [16]. in a study of cancer trials in the UK, studies
that included patient input were twice as likely to suc-
cessfully hit their recruitment targets [20]. Use of the
NPS might provide an opportunity to benchmark trials
and see whether patient input improves satisfaction. Al-
though not directly comparable, a recent cross-industry
survey suggests that currently, the level of patient satis-
faction ascribed to trials is only comparable in the con-
sumer world to some of the worst experiences reported
in the field [21]; dealing with internet service providers,
utility companies, or health insurers are often held up as
unpleasant ordeals and this data speaks to substantial
room for improvement if we are to encourage partici-
pants to enroll.
The main barrier to taking part in trials appeared to
be a lack of awareness, with most patients (61%) not be-
ing invited to take part by their physicians. Clinic ap-
pointments for complex chronic conditions are often too
brief to adequately manage all aspects of care, coordin-
ation, education, and documentation, let alone to also
perform adequate informed consent procedures for a de-
tailed protocol. Infrastructure issues may be important
here; McDonald et al. (2006) found that the most im-
portant predictor of successful trial recruitment was hav-
ing a dedicated trial manager (OR 3.8, 95%CI 0.79–
36.14). Embi et al. [22] found significant improvements
when an automated software system was integrated with
electronic health records, and the increasing move to-
wards electronic systems for records management might
be one opportunity to match eligible participants to en-
rolling trials. Disease advocacy groups may also facilitate
enrollment with patient-facing features such as clinical
trial awareness meetings and advocacy initiatives [23] or
online tools such as the Michael J Fox Foundation’s Fox
Trial Finder [24]. PatientsLikeMe provides its members
an automated tool that matches them to trials for which
they might be eligible on the basis of public data from
ClinicalTrials.gov, although a recent review found that
this data source itself might be less than perfect for such
purposes [25].
In line with the literature [26, 27] females and non-
whites were under-represented amongst the patients
who had experience of being in a trial. Patients in hard-
to-reach group may need further outreach, such as
meeting patients where they are at major community
events, churches, senior centers, and schools (Institute
of Medicine, 2012). Once participation was offered, com-
monly cited reasons for declining to participate were fac-
tors such as inconvenience to travel sites, concerns over
side effects, and chance of getting a placebo. Given that
these research-related factors might be a deterrent to
participation, researchers could consider more patient-
centered trial designs that emphasize at-home testing,
put systems in place to help patients report and cope
with side effects, or use novel designs such as adaptive
or pragmatic trials to reduce use of placebo. Communi-
cating these patient-centric innovations concisely in re-
cruitment materials could be a key part of stimulating
interest in a new study; sometimes the features of a clin-
ical trial are so obscured in recruitment materials that
patients incorrectly infer that benefits such as out-of-
pocket expenses are not covered when they are [28].
Previous studies have found that altruism and per-
sonal benefits are among the key motivators for
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participating in trials generally [29] and our study
replicated this finding. From the patient standpoint,
the majority of participants cited that it was also im-
portant to get medical bills covered (96%) or get the
trial results once the trial was over (95%), and there
is some evidence to suggest that in practice most trial
participants never receive this feedback [30]. Under-
standing and addressing such patient needs and ex-
pectations are critical steps forward towards designing
patient-centered trials rather than assuming that al-
truism alone will drive recruitment efforts.
In the current study, ALS patients were less concerned
about undesirable aspects of trials such as potential
negative impact on health and side effects of new treat-
ment. One possible explanation of these findings is that
due to the lack of disease-modifying therapeutics and re-
duced life expectancy, ALS patients may be more des-
perate to find a cure. Other studies considering chronic
conditions have found that cancer trials were more likely
to fulfill their recruitment targets, for instance [20]. Pre-
vious research has found that ALS patients might be
particularly unusual in the lengths that they will go to
self-experiment, including off-label treatments and even
breaking trial protocols to attempt to deduce whether an
experimental treatment is having an effect [16].
Patients with the rarer conditions ALS, PD or MS
were more experienced with trials (36%, 36 and 20% re-
spectively) than patients with the more common T2DM,
fibromyalgia and MDD (13%, 11 and 11%). This may be
a reflection of different factors such as (1) the perceived
severity of their condition; (2) availability of available
therapies, (3) opportunity to choose between trials in the
investigational pipeline, (4) inherent disease characteris-
tics such as exclusionary comorbidities, and (5) engage-
ment with organizations supporting research. Given that
PatientsLikeMe has historically had deep and engaged
communities in ALS, PD, and MS, this may simply
reflect unusually high levels of engagement in these re-
spondent. However, it might be worth briefly considering
the conditions with lower levels of trial participation.
T2DM patients might be less willing to participate in
clinical research because the perceived threat from the
illness is lower than some of the other conditions pro-
filed here. Fibromyalgia trials suffer from an FDA-
mandated discontinuation of all other therapies, with the
exception of acetaminophen, as a requirement for trial
participation, which 84% of patients rated as undesirable
[31]. Mental health disorders such as MDD have previ-
ously been identified as challenging to enroll in clinical
trials due to stigma, trial issues arising from patients
with a heightened risk of suicide, and the availability of
existing therapies [32]. Once enrolled, however, MDD
patients in this study reported some of the highest levels
of satisfaction with their trials.
The merits of the study include utilizing crowdsourced
PPRNs for rapid enrollment and data collection in a
group of patients who have either been in clinical trials
or who have a high degree of interest in taking part in
them. These networks hold promise for optimizing trial
design and operations by enabling researchers to evalu-
ate to patients’ concerns in a way that is fast, repeatable,
and with results that can generalize to a broader popula-
tion easier than individual advocates or small focus
groups. Furthermore, given the participatory nature of
our research, this provides a framework to re-engage pa-
tients for future feedback and evaluate the disease corre-
lates (e.g., severity, treatment use) that may predict trial
preferences in the future. This framework can be
adapted for future studies to elicit trial-specific patient-
centered feedback in real-time that can not only be
targeted to improve recruitment but also ensure that pa-
tient expectations are met from trials.
There are several limitations to the current study de-
sign. The study was cross-sectional survey and hence
subject to selection bias, recall bias, information bias
and social desirability bias. It may represent the patient
voice, but the data are based on subjective self-reports,
the data are derived from a convenience sample, and the
mix of patients is representative of PLM and not neces-
sarily of the medical population at large. The PLM
population skews toward a more activated, educated, fe-
male population with chronic conditions, although this
is typical for many health-oriented sites [33, 34]. Finally,
condition comparisons presented in the study were not
specified a-priori. While adjustments were made for
multiple pairwise comparisons, statistics are purely
exploratory.
Conclusions
Patients are willing and able to take part in clinical trials
for altruistic reasons but are rarely given the opportunity
to do so. Once enrolled, they face an experience that
could be improved upon by consulting with other pa-
tients like them to improve protocol design. Although
patient factors are only one aspect of conducting a suc-
cessful trial there are sound ethical, scientific, and busi-
ness reasons for taking a more patient-centric approach.
Additional file
Additional file 1: Appendix: Survey Questionnaire (DOCX 16 kb)
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